Table 5.
Estimated Cumulative Incidence of Breast and Ovarian Cancer by CJM
| Cancer | Estimated Mutation-Specific Cumulative Incidence of Cancer by Age |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Years |
40 Years |
50 Years |
60 Years |
70 Years |
||||||
| % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |
| Breast cancer | ||||||||||
| BRCA1, no CJM* | 7.0 | 36 | 61 | 72 | 76 | |||||
| 185delAG | 8.5 | 6.1 to 12 | 42 | 32 to 54 | 69 | 56 to 80 | 79 | 68 to 89 | 83 | 72 to 92 |
| 5382insC | 11 | 6.7 to 16 | 49 | 35 to 66 | 76 | 59 to 90 | 86 | 71 to 96 | 89 | 75 to 97 |
| BRCA2, no CJM* | 12 | 48 | 73 | 85 | 90 | |||||
| 6174delT | 4.3 | 2.2 to 8.4 | 20 | 11 to 36 | 37 | 21 to 59 | 48 | 28 to 73 | 55 | 33 to 79 |
| Ovarian cancer | ||||||||||
| BRCA1, no CJM* | 0.0 | 4.4 | 24 | 47 | 60 | |||||
| 185delAG | 0.0 | 0.0 to 1.0† | 4.2 | 2.5 to 7.0 | 23 | 15 to 36 | 46 | 30 to 64 | 58 | 41 to 77 |
| 5382insC | 0.0 | 0.0 to 1.0† | 2.7 | 1.2 to 6.0 | 16 | 7.2 to 32 | 32 | 16 to 58 | 42 | 22 to 71 |
| BRCA2, no CJM* | 0.0 | 0.0 | 5.3 | 23 | 29 | |||||
| 6174delT | 0.0 | 0.0 to 2.2† | 0.0 | 0.0 to 0.7† | 7.0 | 2.6 to 18 | 30 | 12 to 63 | 37 | 15 to 73 |
Abbreviation: CJM, common Jewish mutation.
*
Because baseline risks were adjusted for no CJM or prophylactic surgery, we could not estimate 95% CIs.
†
Upper confidence limits for cells with no observed events were calculated according to Wilson's score method.